WHO ICTRP trial
Screening of regimens to prevent neurotoxicity due to breast cancer treated with…
ChiCTR2500099237 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500099237 |
|---|---|
| Public title | Screening of regimens to prevent neurotoxicity due to breast cancer treated with albumin-bound paclitaxel |
| Scientific title | Screening of regimens to prevent neurotoxicity due to breast cancer treated with albumin-bound paclitaxel |
| Primary sponsor | The Second Affiliated Hospital of Shandong First Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | Breast cancer |
| Interventions | Experimental Group:Sodium monosialoganglioside + albumin-bound paclitaxel chemotherapy regimen;Chinese Medicines Group:Chinese herbal fumigation + albumin-bound paclitaxel chemotherapy regimen;Joint Group:Chinese herbal fumigation + sodium… |
| Registration date | Mar 20, 2025 |
| Target size | Experimental Group:50;Chinese Medicines Group:50;Joint Group:50;Control Group:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: